Chaoju Eye Care Holdings Limited disclosed a Next Day Disclosure Return showing no change to its total issued share capital but confirmed ongoing execution of its 2026 share-repurchase programme.

Key takeaways:

• Latest on-market purchase: On 16 July 2026, the company repurchased 180,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.57 and HKD 2.61, for a total consideration of HKD 0.47 million.

• Share capital unchanged: Issued share capital remained at 705.18 million shares as of 16 July 2026, with no treasury shares held.

• Cumulative 2026 repurchases: Since the current mandate was approved on 12 May 2026, Chaoju Eye Care has bought back 2.18 million shares, representing 0.31% of the company’s issued share base on the mandate date. The authorisation permits repurchases of up to 70.52 million shares, leaving more than 97% of the allowance unused.

• Pending cancellations: Between 2 April and 16 July 2026 the company repurchased multiple tranches totalling 2.18 million shares that are yet to be cancelled; these shares currently remain in the issued share count.

• Moratorium period: In line with Hong Kong listing rules, Chaoju Eye Care is restricted from issuing new shares or transferring treasury shares until 15 August 2026.

All repurchases were conducted on the Hong Kong Stock Exchange and, according to the company, complied with the exchange’s listing rules and all relevant regulations.